Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
Drug guidance

Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia

Condition

Blood and Immune System

Cancer

16 September 2025

-

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended momelotinib for inclusion on the MOH List of Subsidised Drugs for treating myelofibrosis (MF)-related splenomegaly or symptoms in patients with moderate to severe anaemia. This decision was based on momelotinib being unlikely to represent an acceptable use of healthcare resources at the price proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.

Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia (Published 16 Sep 2025) [PDF, 243 KB]

PES Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia (Published 16 Sep 2025) [PDF, 63 KB]

Back to top